Patents Examined by Alana Harris Dent
  • Patent number: 9233144
    Abstract: The present invention concerns new methods for treating cancer by using TYRO3 inhibitors and methods for identifying new molecules of interest for treating cancer.
    Type: Grant
    Filed: September 18, 2009
    Date of Patent: January 12, 2016
    Inventors: Isabelle Bernard-Pierrot, Francois Radvanyi, Yves Allory, Nicolas Stransky
  • Patent number: 9212221
    Abstract: A method of producing form-specific anti-peptide antibodies for a wild type protein and its one amino acid mutated protein using a peptide antigen, by obtaining a protein sequence of the wild type protein and its one amino acid mutated protein, selecting a continuous amino acid sequence without any internal cysteine residues that includes the one amino acid mutated sequence and wild type sequence corresponding to the mutated site at the end of the sequence to obtain a synthetic mutation peptide and a synthetic wild type peptide, conjugating the synthetic peptides to a carrier protein, and immunizing an animal to produce antibodies. Methods of detecting cancer and methods of treating cancer.
    Type: Grant
    Filed: March 3, 2011
    Date of Patent: December 15, 2015
    Assignee: Detroit R & D, Inc.
    Inventor: Hyesook Kim
  • Patent number: 9181552
    Abstract: Materials and Methods for use in treating cell proliferative disorders related to asparagine metabolism are provided. Cell proliferative disorders include such cancers as forms of leukemia, ovarian cancers, melanomas, renal cancers, breast cancers, brain cancers, and other cancers. Methods include the use of RNA interference targeted at asparagine synthetase to enhance the efficacy of L-asparaginase therapies.
    Type: Grant
    Filed: June 2, 2011
    Date of Patent: November 10, 2015
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Philip L. Lorenzi, John N. Weinstein, Natasha J. Caplen
  • Patent number: 9182415
    Abstract: Provided herein are methods and compositions for the prognostic evaluation of a patient suspected of having, or having, cancer by assessing the expression of IMP3 in a biological sample of a patient. Methods can be used at the time of initial diagnosis of malignant tumors to identify a group of patients with a high potential to develop progression or metastasis later. Therefore, methods not only are able to provide very useful prognostic information for patients but also can help clinicians to select a candidate patient likely to benefit from early and aggressive cancer therapy. Methods and compositions for the treatment of cancer associated with expression of IMP3 are also provided.
    Type: Grant
    Filed: January 16, 2013
    Date of Patent: November 10, 2015
    Assignee: University of Massachusetts
    Inventor: Zhong Jiang
  • Patent number: 9155783
    Abstract: This invention relates to the use of a polypeptide in the production of an immunostimulatory agent, said polypeptide comprising a sequence corresponding to the EDA domain of fibronectin, a fragment of the EDA domain which can bind to TLR4 or a variant of said EDA domain or a fragment which can bind to TLR4 and which has a homology of more than 70% with any form or natural fragment of the EDA domain. The invention also relates to the production methods and applications of said agent.
    Type: Grant
    Filed: June 13, 2006
    Date of Patent: October 13, 2015
    Inventors: Claude Leclerc, Juan Jose Lasarte Sagastibelza, Marta Gorraiz Ayala, Jesus Prieto Valtuena
  • Patent number: 9157904
    Abstract: The present invention relates to compositions comprising Wnt antagonists and methods of treating Wnt-associated diseases and disorders, such as cancer, inducing differentiation, and reducing the frequency of cancer stem cells, as well as novel methods of screening for such Wnt antagonists. In particular, the invention discloses soluble FZD, SFRP and Ror receptors and their use.
    Type: Grant
    Filed: January 12, 2011
    Date of Patent: October 13, 2015
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Sanjeev H. Satyal, Satyajit Sujit Kumar Mitra, Austin L. Gurney
  • Patent number: 9145446
    Abstract: The P21 protein is used as a medicament in the treatment of cancer. A conjugate comprises a first region comprising the P21 protein, or a homologue or functional fragment thereof; and a second region comprising a translocation factor.
    Type: Grant
    Filed: October 29, 2009
    Date of Patent: September 29, 2015
    Assignee: Trojan Technologies, Ltd.
    Inventors: Agamemnon Epenetos, Christina Kousparou
  • Patent number: 9140704
    Abstract: Methods for identifying disease-specific markers, in particular breast cancer markers, by electrophoretically separating serum albumin complexes in a biological sample on a membrane are provided. Electrophoretic separation profiles representing different diseases or different cancer stages can be produced, and used in the diagnosis, prognosis and treatment of these diseases. Methods for identification of a cancer peptide fragment comprising a cancer peptide motif are provided. Also provided are breast cancer and other cancer markers and antibodies that specifically recognize these markers.
    Type: Grant
    Filed: July 13, 2010
    Date of Patent: September 22, 2015
    Assignee: Temple University of The Commonwealth System of Higher Education
    Inventors: Frank N. Chang, Phu T. Duong, George P. Tuszynski
  • Patent number: 9132176
    Abstract: The present invention provides oligopeptides comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 4 and 5. The present invention also provides a pharmaceutical composition containing the amino acid sequence of selected from the group consisting of SEQ ID NOs: 3, 4 and 5 formulated for the treatment or prevention of cancer in a subject. Furthermore, the present invention provides a method of inducing immune response using such oligopeptides and pharmaceutical agents.
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: September 15, 2015
    Assignee: OncoTherapy Science, Inc.
    Inventors: Yasuharu Nishimura, Katsunori Imai, Yusuke Nakamura, Takuya Tsunoda
  • Patent number: 9128086
    Abstract: This invention relates to the diagnosis of disease conditions, such as cancer and autoimmune disease, by the analysis of cell-free nucleosomes in samples from individuals. Methods of the invention may include contacting cell-free nucleosomes from a biological fluid sample obtained from the individual with an antibody that binds specifically with a modified histone protein. Binding of the antibody to the nucleosomes is indicative that the individual has the disease condition.
    Type: Grant
    Filed: August 18, 2004
    Date of Patent: September 8, 2015
    Inventors: Lindsay Jane Bawden, Elizabeth Ann Bone, Alan Hastings Drummond, Lindsey Ann Needham
  • Patent number: 9128095
    Abstract: The present invention relates to a biomarker for diagnosing lung cancer and colorectal cancer containing glutaredoxin 3 as an active ingredient, and a kit for diagnosing lung cancer and colorectal cancer using the same biomarker. Glutaredoxin 3 of the present invention is over-expressed in lung cancer tissue and colorectal cancer tissue, which enables early prediction of diagnosis or prognosis of lung cancer and colorectal cancer. Thus, glutaredoxin 3 can be helpfully used as a biomarker for diagnosing lung cancer and colorectal cancer.
    Type: Grant
    Filed: April 15, 2009
    Date of Patent: September 8, 2015
    Inventor: Il Han Kim
  • Patent number: 9115402
    Abstract: The present invention related to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. Specifically, the invention provides a method of identifying tumor specific neoantigens that alone or in combination with other tumor-associated peptides serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor responses.
    Type: Grant
    Filed: May 16, 2011
    Date of Patent: August 25, 2015
    Assignees: Dana-Farber Cancer Institute, Inc., The General Hospital Corporation
    Inventors: Nir Hacohen, Catherine Ju-Ying Wu
  • Patent number: 9096670
    Abstract: According to the present invention there is provided a specific binding member which is specific for and binds directly to the ED-B oncofoetal domain of fibronectin (FN). The invention also provides materials and methods for the production of such binding members.
    Type: Grant
    Filed: October 4, 2013
    Date of Patent: August 4, 2015
    Assignee: PHILOGEN S.P.A.
    Inventors: Dario Neri, Barbara Carnemolla, Luciano Zardi, Gregory Paul Winter
  • Patent number: 9090693
    Abstract: The present invention relates to the treatment of EGFR-mediated disease, particularly cancer, which is resistant to tyrosine kinase inhibitor therapies. Methods for treatment of cancer and reduction of tumor growth in individuals with secondary EGFR mutations, particularly tyrosine kinase domain mutations, resistant to standard therapy are provided. The invention provides methods for the treatment of tyrosine kinase inhibitor resistant cancers with anti-EGFR antibodies. Methods for treatment of recurrent lung cancer, including non-small cell lung carcinoma which is resistant to tyrosine kinase inhibitors, with the antibody anti-EGFR mAb806 are described.
    Type: Grant
    Filed: January 24, 2008
    Date of Patent: July 28, 2015
    Assignee: Dana-Farber Cancer Institute
    Inventor: Kwok-Kin Wong
  • Patent number: 9078915
    Abstract: A method of detecting prostate tumorigenesis in a subject, the method including the steps of (a) obtaining a sample from the prostate of the human subject, (b) detecting quantitatively or semi-quantitatively in the sample a level of expression for PKC-? and (c) comparing the expression level in (b) to a level of expression in a normal control, wherein overexpression of PKC-?, with respect to the control, indicates the presence of prostate cancer in the subject. The present invention is based upon the discovery that PKC-? levels are elevated during prostate tumorigenesis. Furthermore, the proliferation rate of the tumor correlates with the level of PKC-?. The invention also provides methods of treating prostate cancer by administering to the subject a compound that inhibits the expression of PKC-?. The compound can be a small interfering RNA (siRNA) molecule.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: July 14, 2015
    Assignees: University of South Florida, The United States of America as represented by the Department of Veterans Affairs
    Inventors: Mildred Enid Acevedo-Duncan, Hla Y. Win, Raoul Salup
  • Patent number: 9078895
    Abstract: It has now been found that the p53 pathway is inactivated in ocular cancers such as retinoblastoma. As such, the present invention is a method for inducing ocular cancer cell death using a p53 activator. In particular embodiments, the p53 activator blocks the interaction between DM2 or DMX and p53. As the p53 activator induces ocular cancer cell death, a method for preventing or treating ocular cancer is also provided.
    Type: Grant
    Filed: December 5, 2013
    Date of Patent: July 14, 2015
    Assignees: St. Jude Children's Research Hospital, Flanders Interuniversity Institute for Biotechnology, Universiteit Gent, Leiden University Medical Center
    Inventors: Michael A. Dyer, Jean-Christophe Marine, Aart Gerrit Jochemsen
  • Patent number: 9073985
    Abstract: Methods and products for treating proliferative diseases, and wounds, using as a pharmacon an autophagy inhibitor, a glycolytic inhibitor, and/or an agent able to alter cellular production of reactive oxygen, or combination thereof, optionally in combination with one or more chemotherapeutic agents. In some embodiments, the invention combines a 4-aminoquinoline, exemplified by chloroquine, with a glycolytic inhibitor, exemplified by 2-deoxy-D-glucose and anti-VEGF antibodies. The systems and methods of the invention may be used to treat drug-resistant or multi-drug resistant cancers.
    Type: Grant
    Filed: July 14, 2009
    Date of Patent: July 7, 2015
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Martha Karen Newell, Susannah K. Rogers
  • Patent number: 9044382
    Abstract: According to the invention, gene products expressed in a tumor-associated manner and the nucleic acids coding therefor were identified. The invention relates to the therapy and diagnosis of diseases wherein said gene products expressed in a tumor-associated manner are aberrantly expressed. The invention also relates to proteins, polypeptides and peptides which are expressed in a tumor associated manner and to nucleic acids coding therefor.
    Type: Grant
    Filed: May 18, 2005
    Date of Patent: June 2, 2015
    Assignee: Ganymed Pharmaceuticals AG
    Inventors: Özlem Türeci, Ugur Sahin, Michael Koslowski, Stefan Fritz, Harald-Gerhard Geppert
  • Patent number: 9040049
    Abstract: The present invention relates to antibodies and antigen-binding fragments thereof, immunogenic peptide(s), and siRNA molecules which are capable of inhibiting neovascularization and/or angiogenesis and endothelial cell proliferation. The invention relates to antibodies and antigen-binding fragments thereof with specificity towards the metalloprotease domain of ADAM 15 and to immunogenic peptide(s) that elicits such antibodies. The invention also relates to compositions and kits comprising the antibodies and immunogenic peptide(s) of the invention, as well as methods and uses of the antibodies and antigen-binding fragments thereof and immunogenic peptide(s), as well as siRNA molecules.
    Type: Grant
    Filed: March 24, 2009
    Date of Patent: May 26, 2015
    Assignee: Vasgen Limited
    Inventors: Salman Rahman, Yatin Patel, Holger Gerhardt, Andrea Emma Lundkvist
  • Patent number: 8980269
    Abstract: A method for determining whether early stage cancer is present in a subject comprises detecting the expression level of GASP-1 in the subject by detecting the amount of GASP-1 peptide fragments present in a biological sample of the subject. Because cancer can be detected at an early stage, therapeutic targeting may be initiated before cancer reaches late stage (e.g., before the development of overt symptoms). A method for treating early stage cancer in a subject comprises administering to the subject an effective amount of a GASP-1 inhibitor to inhibit the progression of early stage cancer to late stage cancer. A Competitive ELISA capable of detecting GASP-1 peptide fragments at a concentration of less than 1 ng/ml was developed.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: March 17, 2015
    Assignee: Temple University of the Commonwealth System of Higher Education
    Inventors: Frank N. Chang, George P. Tuszynski